FDA Approves Dostarlimab-gxly for dMMR Endometrial Cancer

FDA Approves Dostarlimab-gxly for dMMR Endometrial Cancer

On February 9, 2023, the U.S Food and Drug Administration (FDA) approved dostarlimab-gxly for adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.

For more information, read the FDA announcement, and the GlaxoSmithKline announcement.

Posted 2/10/2023

Upcoming Events

Virtual Oncology Reimbursement Meeting (ORM) | Winter 2026

Virtual Oncology Reimbursement Meeting (ORM) | Winter 2026

Virtual December 9, 2026 at 11:00 AM EST
2027 ACCC Leadership Summit

2027 ACCC Leadership Summit

In Person April 22, 2027 at 6:00 PM EDTWillard InterContinental Hotel, 1401 Pennsylvania Avenue Northwest, Washington, DC, USAWashington